| Patent Number |
Title Of Patent |
Date Issued |
| 7586091 |
Mass spectrometric system and mass spectrometry |
September 8, 2009 |
| After a sample is previously separated into plural components in a channel formed in a microchip (353), the channel is irradiated along a separation direction with a laser beam from a laser oscillator (361) to sequentially ionize each fraction separated in the channel. The ionized fracti |
| 7424191 |
System for measuring the wavelength dispersion and nonlinear coefficient of an optical fiber |
September 9, 2008 |
| A method of simultaneously specifying the wavelength dispersion and nonlinear coefficient of an optical fiber. Pulsed probe light and pulsed pump light are first caused to enter an optical fiber to be measured. Then, the power oscillation of the back-scattered light of the probe ligh |
| 7146085 |
Method and system for measuring the wavelength dispersion and nonlinear coefficient of an optica |
December 5, 2006 |
| A method of simultaneously specifying the wavelength dispersion and nonlinear coefficient of an optical fiber. Pulsed probe light and pulsed pump light are first caused to enter an optical fiber to be measured. Then, the power oscillation of the back-scattered light of the probe ligh |
| 7003202 |
Method and system for measuring the wavelength dispersion and nonlinear coefficient of an optica |
February 21, 2006 |
| A method of simultaneously specifying the wavelength dispersion and nonlinear coefficient of an optical fiber. Pulsed probe light and pulsed pump light are first caused to enter an optical fiber to be measured. Then, the power oscillation of the back-scattered light of the probe ligh |
| 5747502 |
Process for preparing benzo[c]phenanthridinium derivatives, novel compounds prepared by said pro |
May 5, 1998 |
| The present invention relates to benzo[c]phenanthridinium derivative of the general formula A: ##STR1## wherein M and N individually represent a hydroxyl or lower alkoxy group, or M and N simultaneously represent a hydrogen atom or together form a methylenedioxy group, X.sup.- re |
| 5214048 |
Oxetanocins |
May 25, 1993 |
| This invention relates to novel oxetanocins represented by the following general formula (I): ##STR1## wherein R represents a group represented by ##STR2## and their pharmacologically acceptable salts which have antiviral activities. |
| 5179084 |
Antiviral phosphoric acid esters of oxetanocins |
January 12, 1993 |
| The present invention relates to phosphoric acid esters of oxetanocins having an antiviral activity which are represented by general formula (I): ##STR1## wherein R.sub.1 represents a phosphoric acid ester residue, X represents hydrogen, hydroxy or hydroxymethyl group, and B represen |
| 5128493 |
Platinum complexes |
July 7, 1992 |
| A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1 and R.sub.2 are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.3 and R.sub.4 are each a hydrogen atom or a lo |
| 5068376 |
Novel platinum complexes |
November 26, 1991 |
| A diamine platinum (II) complex represented by the general formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## wherein R.sub.5 and R |
| 5041447 |
Oxetanocin-related compounds and pharmaceutical compositions containing them |
August 20, 1991 |
| This invention relates to oxetanocin-related compounds represented by the following formula (I): ##STR1## [in formula (I), R.sub.1, Y and B have the following meanings: (a) R.sub.1 represents --CH.sub.2 OH or --CH.sub.2 OCO-(alkyl),(b) Y represents ##STR2## provided that R.s |
| 4987246 |
Novel platinum complexes |
January 22, 1991 |
| A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1 and R.sub.2 are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.3 and R.sub.4 are each a hydrogen atom or a lo |
| 4956504 |
Novel spergualin-related compounds and process for producing the same |
September 11, 1990 |
| The present invention relates to novel Spergualin-related compounds represented by the general formula [I] ##STR1## (wherein X is ##STR2## R is --H or --CH.sub.2 OH; R.sub.1 is --H, ##STR3## R.sub.2 is a residue obtained by removing, from an amino acid or peptide, the |
| 4921984 |
Novel platinum complexes |
May 1, 1990 |
| A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.5 and |
| 4864043 |
Platinum complexes |
September 5, 1989 |
| A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.5 and |
| 4861905 |
Platinum complexes |
August 29, 1989 |
| A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1 and R.sub.2 are each a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.3 and R.sub.4 are each a hydrogen atom or a lo |
| 4824955 |
Selenium oxy chloride-pyridine or bipyridine complexes |
April 25, 1989 |
| This invention relates to the novel selenium compounds which are useful as an antineoplastic agent. The compounds are represented by the general formula (I):wherein R, X, A and Y represent the groups specified below, a represents a number of 0 or 1, b represents a number of 0, 1 or 2, an |
| 4808703 |
Novel 3-(4'-aminobutylamino) propylaminobleomycin derivatives |
February 28, 1989 |
| Disclosed is a 3-(4'-aminobutylamino) propylaminobleomycin having low pulmonary toxicity, which expressed by the following general formulawherein [BX] represents a residue remaining after removing a hydroxyl group from the carboxyl group of bleomycinic acid, A represents a group of the f |
| 4737589 |
Platinum Complexes |
April 12, 1988 |
| A diamine platinum (II) complex represented by the general formula ##STR1## [wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each a hydrogen atom or a lower alkyl group; and two X's are each a halogen atom or jointly form a group represented by ##STR2## (wherein R.sub.5 and |
| 4607114 |
Novel platinum complexes |
August 19, 1986 |
| This invention relates to a novel platinum-diamine complexes represented by the general formula: ##STR1## wherein R.sub.1 and R.sub.2 each represents a lower alkyl group having 1 to 3 carbon atoms or jointly represent an alkylene group having 3 to 6 carbon atoms; two X's each rep |
| 4568490 |
Aminopropylaminobleomycin derivatives and process for preparation thereof |
February 4, 1986 |
| An aminopropylaminobleomycin represented by the following formula or a salt thereof, which is minimized in side effects such as pulmonary toxicity:wherein[BX] represents the acyl group of bleomycinic acid whose formula differs from that of bleomycin acid by the removal of the hydroxyl group |
| 4556735 |
Spergualin-related compounds having a phenylene group as well as a process for producing the sam |
December 3, 1985 |
| The invention relates to Spergualin-related compounds of the formula: ##STR1## (wherein R.sub.1 is a lower alkylene group which may be substituted by a hydroxymethyl group; X is a hydrogen atom or a halogen atom; m and n are each 0 or an integer of 1 to 5) and salts thereof and a pro |
| 4537880 |
Aminopropylaminobleomycin derivatives and process for preparation thereof |
August 27, 1985 |
| An aminopropylaminobleomycin represented by the following formula or a salt thereof, which is minimized in side effects such as pulmonary toxicity:wherein[BX] represents the acyl group of bleomycinic acid whose formula differs from that of bleomycin acid by the removal of the hydroxyl group |
| 4529549 |
Spergualin-related compounds and process for the preparation thereof |
July 16, 1985 |
| This invention relates to a novel spergualin-related compound and a process for the production thereof. The novel compound, which has a high antitumor activity, is represented by the general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, hydroxyl group, or an alipha |
| 4500452 |
(Amido)N-substituted bleomycins, salts thereof and process for preparation thereof |
February 19, 1985 |
| A promising carcinostatic (amido)N-substituted bleomycin represented by the following formula, or a salt thereof and a process for the preparation thereof: ##STR1## wherein BM represents a moiety of bleomycin skeleton; X represents an alkyl of 1 to 18 carbon atoms, an aminoalkyl |
| 4472304 |
(Amido)N-substituted bleomycins, salts thereof and process for preparation thereof |
September 18, 1984 |
| A promising carcinostatic (amido)N-substituted bleomycin represented by the following formula, or a salt thereof and a process for the preparation thereof: ##STR1## wherein BM represents a moiety of bleomycin skeleton; X represents an alkyl of 1 to 18 carbon atoms, an aminoalkyl |
| 4327081 |
Method of enhancing absorption of antitumor agent into gastro-intestinal tumor site and orally a |
April 27, 1982 |
| This invention relates to a method for selectively enhancing absorption of 5-fluorouracil, bleomycins or bleomycin derivatives into the gastrointestinal tumor site by orally administering such substance together with an alkali metal salt of polyacrylic acid, and an orally administrab |
| 4273761 |
Method of enhancing absorption of antitumor agent into gastrointestinal tumor site and orally ad |
June 16, 1981 |
| This invention relates to a method for selectively enhancing absorption of 5-fluorouracil, bleomycins or bleomycin derivatives into the gastrointestinal tumor site by orally administering such substance together with an alkali metal salt of polyacrylic acid, and an orally administabl |
